Literature DB >> 23659929

Significant dermatological side effects of intravenous immunoglobulin.

Carrie B Hurelbrink1, Judith M Spies, Con Yiannikas.   

Abstract

Intravenous immunoglobulin (IVIg) is an essential treatment for many neurological, immunological and haematological conditions. However, the severity of its rare adverse effects is often underrecognised. We report a series of 15 patients receiving IVIg for neurological and immunological disorders who developed severe skin reactions. Despite pre-medication, nearly all patients ceased IVIg due to the severity of the adverse response. Interestingly, the majority of patients were male and two-thirds were receiving treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or another inflammatory or demyelinating neuropathy. This marked propensity for male patients with CIDP to develop significant dermatological reactions following IVIg administration has not previously been described. Mechanisms involving the underlying autoimmunity inherent to this condition may play a role.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse effects; Chronic inflammatory demyelinating polyradiculoneuropathy; Intravenous immunoglobulin; Skin reaction

Mesh:

Substances:

Year:  2013        PMID: 23659929     DOI: 10.1016/j.jocn.2012.10.026

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  Diffuse exanthematous drug eruption associated with intravenous immunoglobulin.

Authors:  Anish Paudel; Sijan Basnet; Biswaraj Tharu; Nidrit Bohra
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-19

Review 2.  Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

Authors:  Anne Louise Oaklander; Michael Pt Lunn; Richard Ac Hughes; Ivo N van Schaik; Chris Frost; Colin H Chalk
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

3.  Predictive factors of first dosage intravenous immunoglobulin-related adverse effects in children.

Authors:  Jun Kubota; Shin-Ichiro Hamano; Atsuro Daida; Erika Hiwatari; Satoru Ikemoto; Yuko Hirata; Ryuki Matsuura; Daishi Hirano
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.